Marek Trněný
Impact in
- Pathology and Forensic Medicine top 0.01%
- Lymphoma Diagnosis and Treatment
- Genetics top 0.05%
- Chronic Lymphocytic Leukemia Research
Papers in
-
- Lymphoma Diagnosis and Treatment 263
- Genetics 171
- Chronic Lymphocytic Leukemia Research 161
- Co-authors
- Devinder Singh Gill (10 shared papers)Craig H. Moskowitz (8 shared papers)Nicolas Mounier (7 shared papers)David C. Linch (6 shared papers)Norbert Schmitz (8 shared papers)Josette Brière (6 shared papers)Ofer Shpilberg (9 shared papers)Christian Gisselbrecht (9 shared papers)
- Journals
- Blood (92 papers)Hematological Oncology (37 papers)Journal of Clinical Oncology (22 papers)Blood Advances (12 papers)Haematologica (11 papers)
- Partner nations
- CzechiaUnited StatesUnited Kingdom
In The Last Decade
Marek Trněný
367 papers receiving 19.7k citations
Marek Trněný's Hit Papers
Peers
Comparison fields: 5 of 118
- Pathology and Forensic Medicine 13.4k
- Genetics 7.7k
- Oncology 8.5k
- Immunology 3.6k
- Neurology 2.4k
Countries citing papers authored by Marek Trněný
This map shows the geographic impact of Marek Trněný's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marek Trněný with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marek Trněný more than expected).
Fields of papers citing papers by Marek Trněný
This network shows the impact of papers produced by Marek Trněný. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marek Trněný. The network helps show where Marek Trněný may publish in the future.
Co-authors
The 25 scholars most cited alongside Marek Trněný, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 388 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Hit paper breakdown → | 2006 | 1705 |
| 2 | Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial Hit paper breakdown → | 2010 | 1557 |
| 3 | Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era Hit paper breakdown → | 2010 | 1349 |
| 4 | Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial Hit paper breakdown → | 2016 | 774 |
| 5 | CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group Hit paper breakdown → | 2011 | 653 |
| 6 | Obinutuzumab for the First-Line Treatment of Follicular Lymphoma Hit paper breakdown → | 2017 | 597 |
| 7 | Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial Hit paper breakdown → | 2018 | 562 |
| 8 | Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Hit paper breakdown → | 2018 | 554 |
| 9 | Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Hit paper breakdown → | 2022 | 522 |
| 10 | First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial Hit paper breakdown → | 2016 | 497 |
| 11 | 2010 | 476 | |
| 12 | Treatment of Older Patients with Mantle-Cell Lymphoma Hit paper breakdown → | 2012 | 402 |
| 13 | Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study Hit paper breakdown → | 2015 | 375 |
| 14 | A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study Hit paper breakdown → | 2020 | 365 |
| 15 | 2017 | 341 | |
| 16 | AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma Hit paper breakdown → | 2019 | 320 |
| 17 | 2018 | 303 | |
| 18 | 2016 | 277 | |
| 19 | 2017 | 259 | |
| 20 | 2015 | 247 |
About Marek Trněný
Marek Trněný is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Hematology and Immunology, having authored 388 papers that have together received 20.1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (263 papers), Chronic Lymphocytic Leukemia Research (161 papers), CAR-T cell therapy research (52 papers), Viral-associated cancers and disorders (51 papers), CNS Lymphoma Diagnosis and Treatment (34 papers), Acute Lymphoblastic Leukemia research (26 papers), Chronic Myeloid Leukemia Treatments (24 papers) and Monoclonal and Polyclonal Antibodies Research (21 papers). The work is most often cited by research in Pathology and Forensic Medicine (13.4k citations), Genetics (7.7k citations), Oncology (8.5k citations), Immunology (3.6k citations) and Neurology (2.4k citations). Marek Trněný has collaborated with scholars based in Czechia, United States and United Kingdom. Frequent co-authors include Devinder Singh Gill, Craig H. Moskowitz, Nicolas Mounier, David C. Linch, Norbert Schmitz, Josette Brière, Ofer Shpilberg, Christian Gisselbrecht, Nicolas Ketterer and Dávid Ma. Their work appears in journals such as Blood, Hematological Oncology, Journal of Clinical Oncology, Blood Advances and Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.